BioMendics is working to transform the care of patients suffering rare dermatologic disorders with their lead clinical program focused on epidermolysis bullosa simplex.
The company’s proprietary small molecule liquid crystal medications hold the restorative potential to mend blistering and fragile skin, restoring hope for a brighter future to patients and their families.
BioMendics will soon be recruiting for an Epidermolysis Bullosa Focus Group and our Phase II, TAMES-02 Clinical Trial in EB Simplex. Click here to sign up to receive more information.
Learn More
BioMendics is committed to advancing its small molecule liquid crystal MTORX™ Technology to develop life-enhancing medicines for people suffering from epidermolysis bullosa, epidermolytic ichthyosis, pachyonychia congenita, and other rare dermatologic disorders.
Learn More
If you would like to be part of a team that is working together to advance science that changes lives, explore our open positions, and let us hear from you!
Learn More
At BioMendics, we’re committed to developing
safe and effective treatments for rare skin
disorders like epidermolysis bullosa (EB),
epidermolysis ichthyosis (EI), pachyonychia congenita (PC), and scleroderma.